It’s time to talk about selective androgen receptor modulators (SARMs), with a particular focus on Ostarine (formerly in collaboration with Merck ). It is also found under the names S-22, GTx-024 and MK-2866.
The novelty is that Ostarine is now among doping users around the world. “What is Ostarine?”, You may ask, well let’s see. Ostarine mk 2866 is a drug developed by American GTX Pharmaceuticals, and is SARM, which is currently the longest in its clinical trials, the FDA-approved drug approval system that is used around the world.
Clinical trials are conducted in three phases, which must be successful before the drug can be approved and implemented for certain indications (disorders). If a drug has already been approved for an indication, you may skip some of the work if it is approved for a new indication. Clinical trials should verify that a drug is safe and works as claimed. Drug approval from start to finish costs about 5-15,000,000,000 crowns and less than 5% of all drugs that start clinical trials when approved.
Ostarine was originally developed to treat bone loss but has also been shown to be anabolic in muscles. It is a SARM, which means it binds the androgen receptor, that is, the same as testosterone and other anabolic steroids, but it is NOT steroid.